Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome
| Autor: | Anthony S. Zembillas, Kajal S. Patel, Erika M. Gallagher, Jessica E Lau |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Urate Oxidase medicine.medical_treatment Urology Hyperuricemia 030204 cardiovascular system & hematology Overweight Pharmacology Gout Suppressants 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Renal Dialysis medicine Rasburicase Humans Pharmacology (medical) Treatment Failure Dialysis Aged Retrospective Studies business.industry Incidence (epidemiology) Middle Aged medicine.disease Uric Acid Tumor lysis syndrome Oncology chemistry 030220 oncology & carcinogenesis Retreatment Disease Progression Uric acid Female medicine.symptom Tumor Lysis Syndrome business Body mass index medicine.drug |
| Zdroj: | Journal of Oncology Pharmacy Practice. 23:333-337 |
| ISSN: | 1477-092X 1078-1552 |
| DOI: | 10.1177/1078155216644975 |
| Popis: | Rasburicase is a recombinant urate oxidase enzyme administered for treatment of hyperuricemia associated with tumor lysis syndrome. Studies demonstrate effectiveness of single fixed-dose rasburicase as compared to the FDA-approved dose of 0.2 mg/kg intravenously daily for up to five days. Doses in these studies range from 1.5 mg to 7.5 mg. Our study evaluated outcomes in patients who received single 4.5 mg fixed-dose rasburicase. This retrospective, IRB-approved chart review evaluated adult oncology subjects who received fixed-dose rasburicase between January 2007 and April 2014. The primary outcome was percentage of patients with normalization of uric acid (level 2) versus non-overweight patients. Initial failure was defined as need for additional doses or progression to dialysis within one week of the initial fixed-dose. In the 128 patients included, the mean baseline uric acid level was 14.84 mg/dL. Of the 112 patients with a follow-up uric acid level, 68% achieved normalization within 24 h of rasburicase administration. Thirty-eight patients received additional treatment: 10 received additional dose(s) and 28 underwent dialysis. Normalization of uric acid in overweight versus non-overweight patients was 66% and 73%, respectively. Overall, a single 4.5 mg fixed-dose of rasburicase effectively normalized uric acid in 68% of patients within 24 h. Further studies are needed to determine the optimal single fixed-dose necessary for treatment response across all patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|